Literature DB >> 23839551

Evaluation of Mapleson systems for administration of inhaled nitric oxide.

I Kukita1, K Okamoto, T Sato, Y Shibata, K Shiihara, K Kikuta.   

Abstract

To assess the safety of nitric oxide (NO) inhalation during manual-controlled ventilation using Mapleson A, D, and F systems, we examined nitrogen dioxide (NO2) production using a chemiluminescence analyzer. The NO concentration was changed from 0 to 19 parts per million (ppm), and at each level of NO the oxygen (O2) concentration was changed from 21% to 100%. The NO2 concentration was observed to increase when either the O2 or NO concentration was increased. The maximum NO2 concentrations (mean ± standard deviation) of the Mapleson A, D, and F systems were 0.20±0.03, 0.15±0.03, and 0.17±0.02 ppm, respectively, when the concentrations of NO and O2 were 19 ppm and 100%, respectively. The NO2 concentrations of the Mapleson A system were significantly higher than those of either the Mapleson D or F system at 4, 8, and 12 ppm NO and 100% O2, and than that of the Mapleson D system at 19 ppm NO and 100% O2. From the viewpoint of NO2 production, we suggest that the Mapleson D and F systems are safer than the Mapleson A system when manual-controlled ventilation is required.

Entities:  

Year:  1996        PMID: 23839551     DOI: 10.1007/BF02482067

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  23 in total

1.  Safety guidelines for use of nitric oxide.

Authors:  L Foubert; B Fleming; R Latimer; M Jonas; A Oduro; C Borland; T Higenbottam
Journal:  Lancet       Date:  1992-06-27       Impact factor: 79.321

2.  Rebreathing during controlled respiration with various semiclosed anesthetic systems.

Authors:  D J WATERS; W W MAPLESON
Journal:  Br J Anaesth       Date:  1961-08       Impact factor: 9.166

3.  EDRF/nitric oxide. The endogenous nitrovasodilator and a new cellular messenger.

Authors:  R A Johns
Journal:  Anesthesiology       Date:  1991-12       Impact factor: 7.892

4.  Inhalation of nitric oxide reduced pulmonary hypertension after cardiac surgery in a 3.2-kg infant.

Authors:  H Selldén; P Winberg; L E Gustafsson; B Lundell; K Böök; C G Frostell
Journal:  Anesthesiology       Date:  1993-03       Impact factor: 7.892

5.  Nitric oxide and the lung.

Authors:  W M Zapol; S Rimar; N Gillis; M Marletta; C H Bosken
Journal:  Am J Respir Crit Care Med       Date:  1994-05       Impact factor: 21.405

6.  Successful use of inhaled nitric oxide for treatment of severe hypoxemia in an infant with total anomalous pulmonary venous return.

Authors:  K Okamoto; T Sato; M Kurose; I Kukita; H Fujii; K Taki
Journal:  Anesthesiology       Date:  1994-07       Impact factor: 7.892

7.  Relief of severe pulmonary hypertension after closure of a large ventricular septal defect using low dose inhaled nitric oxide.

Authors:  M Berner; M Beghetti; B Ricou; J C Rouge; R Prêtre; B Friedli
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

8.  Agonist-induced endothelium-dependent relaxation in rat thoracic aorta may be mediated through cGMP.

Authors:  R M Rapoport; F Murad
Journal:  Circ Res       Date:  1983-03       Impact factor: 17.367

9.  Inhaled nitric oxide for the adult respiratory distress syndrome.

Authors:  R Rossaint; K J Falke; F López; K Slama; U Pison; W M Zapol
Journal:  N Engl J Med       Date:  1993-02-11       Impact factor: 91.245

10.  Pulmonary performance of elderly normal subjects and subjects with chronic obstructive pulmonary disease exposed to 0.3 ppm nitrogen dioxide.

Authors:  P E Morrow; M J Utell; M A Bauer; A M Smeglin; M W Frampton; C Cox; D M Speers; F R Gibb
Journal:  Am Rev Respir Dis       Date:  1992-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.